Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.07.23	Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy (Businesswire)
21.07.23	Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility (Businesswire)
19.07.23	Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate (Businesswire)
28.06.23	FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency (Businesswire)
27.06.23	FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec (Businesswire)
26.06.23	Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus (Businesswire)
23.06.23	FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata (Businesswire)
22.06.23	Pfizer Declares Third-Quarter 2023 Dividend (Businesswire)
21.06.23	Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval (Businesswire)
20.06.23	Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts (Businesswire)
06.06.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.23	Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)
31.05.23	U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults (Businesswire)
30.05.23	Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial (Businesswire)
25.05.23	Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting (Businesswire)
25.05.23	Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 (Businesswire)
18.05.23	FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization (Businesswire)
17.05.23	Pfizer Prices $31,000,000,000 Debt Offering (Businesswire)
15.05.23	Pfizer Announces Proposed Notes Offering (Businesswire)
02.05.23	Pfizer Reports First-Quarter 2023 Results (Businesswire)
27.04.23	U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children (Businesswire)
26.04.23	Pfizer Declares Second-Quarter 2023 Dividend (Businesswire)
13.04.23	Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 (Businesswire)
04.04.23	FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI (Businesswire)
21.03.23	Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts (Businesswire)
16.03.23	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ (Businesswire)
13.03.23	Pfizer Invests $43 Billion to Battle Cancer (Businesswire)
10.03.23	Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval (Businesswire)
28.02.23	Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults (Businesswire)
27.02.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
22.02.23	Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance (Businesswire)
21.02.23	U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review (Businesswire)
16.02.23	Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study (Businesswire)
16.02.23	Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults (Businesswire)
10.02.23	FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib) (Businesswire)
09.02.23	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
31.01.23	PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE (Businesswire)
17.01.23	Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries (Businesswire)
06.01.23	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children (Businesswire)
03.01.23	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
28.12.22	U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents (Businesswire)
21.12.22	Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis (Businesswire)
20.12.22	Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts (Businesswire)
10.12.22	Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial (Businesswire)
09.12.22	Pfizer Declares First-Quarter 2023 Dividend (Businesswire)
08.12.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (Businesswire)
07.12.22	U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults (Businesswire)
06.12.22	Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease (Businesswire)
01.12.22	Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day (Businesswire)
16.11.22	Form 4 78003 (RSS)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Pfizer Inc Cert.Deposito Arg.Repr. 0.5 Shs

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten